Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Maipl Therapeutics
AddedFeb 18, 2024
UpdatedJun 18, 2026
Maipl Therapeutics

Maipl Therapeutics

Pre-Seed

Maipl Therapeutics: NY-based medical firm innovating first-in-class medicines for endometriosis and more.

HQ
Scarsdale, NY, US
Founded
2023
Overview
Compare
Fundraising
Employees
Website

Maipl Therapeutics, founded in Scarsdale, New York, is committed to developing innovative, first-in-class medicines targeting endometriosis and other diseases. Their core mission is to create highly selective treatments that address underlying causes of various conditions without affecting essential bodily functions. The company's flagship product, MA-7107, is a potent inhibitor of prostaglandin F2α signaling, designed to treat diseases by selectively antagonizing this pathway.

Notable figures associated with Maipl Therapeutics include leading scientists and medical professionals dedicated to advancing precision therapies. The company has garnered attention for its groundbreaking approach to treating conditions traditionally underserved by existing pharmaceuticals. By focusing on selective inhibition of prostaglandin pathways, Maipl Therapeutics aims to offer safer and more effective treatment options, potentially transforming the landscape of medical therapeutics for diseases like endometriosis.

Maipl Therapeutics - Similar Companies

Maia Pharmaceuticals logo

Maia Pharmaceuticals

maiapharma.com

MDI Therapeutics logo

MDI Therapeutics

Mahzi Therapeutics logo

Mahzi Therapeutics

mahzi.com

Marlinspike Therapeutics logo

Marlinspike Therapeutics

ProFound Therapeutics logo

ProFound Therapeutics

profoundtx.com

Moerae Matrix logo

Moerae Matrix

moeraematrix.com

Initial Therapeutics logo

Initial Therapeutics

initialtx.com

Mistral Therapeutics logo

Mistral Therapeutics

Plumeria Therapeutics logo

Plumeria Therapeutics

Pliant Therapeutics logo

Pliant Therapeutics

pliantrx.com

Exalys Therapeutics logo

Exalys Therapeutics

Marius Pharmaceuticals logo

Marius Pharmaceuticals

mariuspharma.com

Montai Health logo

Montai Health

montai.com

Manistee Therapeutics logo

Manistee Therapeutics

Haima Therapeutics logo

Haima Therapeutics

Maipl Therapeutics - Quick Facts

Who are Maipl Therapeutics' competitors?

Companies similar to Maipl Therapeutics include Maia Pharmaceuticals, MDI Therapeutics, Mahzi Therapeutics and Marlinspike Therapeutics.

When was Maipl Therapeutics founded?

Maipl Therapeutics was founded in 2023.

Where is Maipl Therapeutics' headquarters located?

Maipl Therapeutics' headquarters is located in Scarsdale, NY, US.

When was Maipl Therapeutics' last funding round?

Maipl Therapeutics' most recent funding round was for $135k (USD) in December 2023.

How much has Maipl Therapeutics raised to-date?

As of Dec 15, 2023, Maipl Therapeutics has raised a total of $135k (USD).

How many employees does Maipl Therapeutics have?

Maipl Therapeutics has 7 employees as of Feb 4, 2024.

Maipl Therapeutics - Classification

Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Medicines
  • Therapeutics
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified